The anti-IL-6R antibody Tocilizumab has yielded good responses in clinical trials for rheumatoid arthritis and Crohn's disease [15,49], but no experiences with Tocilizumab in MS therapy are published. The gene discussed is IL6R; the disease is rheumatoid arthritis.